# Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Source: https://onco.cc/trials/nct05043090/  
OnCo record `nct05043090` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Savolitinib, Durvalumab, Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC is a phase 3 interventional study registered as NCT05043090 by AstraZeneca, with 148 participants enrolled, started 2021-10-28 and due to reach its primary completion in 2025-12-31. Interventions recorded: savolitinib, durvalumab, sunitinib. Conditions listed: Papillary Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05043090
- Phase: 3
- Setting: A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
- Sponsor: AstraZeneca
- Enrolled: 148

## Sources

- ClinicalTrials.gov NCT05043090: https://clinicaltrials.gov/study/NCT05043090

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Savolitinib](https://onco.cc/drugs/savolitinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05043090.json